title: Postmenopausal endometrial hyperplasia: role of danazol therapy.
abstract: OBJECTIVE
  To confirm the effectiveness of danazol in the management of simple or complex endometrial hyperplasia without atypical features, as has been demonstrated previously.
  
  
  METHODS
  Seventy-six patients affected by postmenopausal histologically-confirmed endometrial hyperplasia with uterine bleeding were submitted to danazol therapy at a dose of 400 mg/day for 3 consecutive months.
  
  
  RESULTS
  After cessation of treatment, 82.8% of the patients (63/76 enrolled) showed a conversion of the hyperplasia into atrophic (65.8%), secretory (11.9%) or proliferative (4.2%) endometrium at the histological examination. Uterine bleeding disappeared, during the therapy, in 90% of the responders (59/63).
  
  
  CONCLUSIONS
  Although 17.1% of the women had a persistence of the hyperplasia and 8.4% of the symptom-free women relapsed after 4 months of follow-up, this experience confirms the effectiveness of danazol therapy in hyperplastic endometrial lesions. Nevertheless, a study comparing danazol and progestin therapy is required.
authors.affiliation: Department of Gynecologic Oncology, Regina Elena Cancer Institute, Rome, Italy.
authors.forename: L
authors.initials: L
authors.lastname: Mariani
authors.forename: A
authors.initials: A
authors.lastname: Sedati
authors.forename: R
authors.initials: R
authors.lastname: Giovinazzi
authors.forename: R
authors.initials: R
authors.lastname: Sindico
authors.forename: G
authors.initials: G
authors.lastname: Atlante
mesh_terms: D000368:Aged; D003613:Danazol / Q000008:administration & dosage*; D004714:Endometrial Hyperplasia / Q000188:drug therapy* / Q000473:pathology; D004717:Endometrium / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008875:Middle Aged; D017698:Postmenopause; D012008:Recurrence
chemical_list: D003613:Danazol